Efficacy and Safety for the Acute Treatment of Migraine: Results of a Randomized, placebo-controlled Trial


Home \| About Dr. Robbins \| Archived Articles \| Headache Books \| Topic Index

Back to List

Title:

Author:
Date:
Source:

Efficacy and Safety for the Acute
Treatment of Migraine: Results
of a Randomized, placebo-controlled Trial
Silbertstein S., et al.
Posted July 2003
Presented at: 45th Annual Scientific Meeting
American Headache Society
June 19-22, 2003; Chicago, Illinois

Objectives: To examine the safety, tolerability and efficacy of rofecoxib 25 and 50 mg. for the acute treatment of migraine.

Conclusions: Rofecoxib 25 and 50 mg. were generally well-tolerated and demonstrated statistically significant and clinically relevant superiority over placebo on virtually all clinically important outcome measures when used as acute therapy in patients with moderate or severe migraine attacks with or without aura.

Home | About Dr. Robbins | Archived Articles | Headache Books | Topic Index